Published in J Control Release on April 13, 2005
Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv (2010) 1.13
Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release (2013) 0.98
Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity. Mol Pharm (2010) 0.97
Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine (2014) 0.96
Thermosensitive liposomes modified with poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers for triggered release of doxorubicin. Biomacromolecules (2010) 0.92
Localized delivery of doxorubicin in vivo from polymer-modified thermosensitive liposomes with MR-guided focused ultrasound-mediated heating. J Control Release (2014) 0.83
Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell (2011) 4.04
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther (2006) 2.40
Signaling pathways governing stem-cell fate. Blood (2007) 2.38
Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res (2008) 2.20
Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst (2007) 2.03
Hematopoietic stem cell responsiveness to exogenous signals is limited by caspase-3. Cell Stem Cell (2008) 1.94
The liposomal formulation of doxorubicin. Methods Enzymol (2005) 1.62
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (2007) 1.56
Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78. Cell Stem Cell (2011) 1.47
Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling. Ann N Y Acad Sci (2009) 1.45
Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids. Biophys J (2003) 1.43
Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol Ther (2004) 1.39
A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res (2011) 1.33
Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res (2006) 1.31
In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med (2004) 1.20
Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene (2005) 1.14
Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J (2006) 1.14
Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis (2009) 1.13
Direct observation and characterization of DMPC/DHPC aggregates under conditions relevant for biological solution NMR. Biochim Biophys Acta (2004) 1.12
Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med (2006) 1.08
Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother (2009) 1.07
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One (2013) 1.04
Assembly and structural analysis of a covalently closed nano-scale DNA cage. Nucleic Acids Res (2007) 1.04
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1.04
Self-assembly of beta-cyclodextrin in water. Part 1: Cryo-TEM and dynamic and static light scattering. Langmuir (2006) 1.03
The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. J Pharm Sci (2010) 1.02
Dynamic analysis of gene expression and genome-wide transcription factor binding during lineage specification of multipotent progenitors. Cell Stem Cell (2013) 1.01
Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta (2002) 1.00
Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther (2007) 1.00
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res (2008) 0.99
Effect of lipid headgroup composition on the interaction between melittin and lipid bilayers. J Colloid Interface Sci (2007) 0.99
Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem (2002) 0.99
Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta (2006) 0.99
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther (2006) 0.99
Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther (2008) 0.98
Population-based study of non-infectious rhinitis in relation to occupational exposure, age, sex, and smoking. Am J Ind Med (2002) 0.97
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta (2004) 0.95
Docosahexaenoic acid stabilizes soluble amyloid-beta protofibrils and sustains amyloid-beta-induced neurotoxicity in vitro. FEBS J (2007) 0.94
All-or-none membrane permeabilization by fengycin-type lipopeptides from Bacillus subtilis QST713. Biochim Biophys Acta (2011) 0.94
Novel findings in Swedish patients with MYH-associated polyposis: mutation detection and clinical characterization. Clin Gastroenterol Hepatol (2006) 0.93
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci (2005) 0.92
Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta (2002) 0.92
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release (2005) 0.91
Interactions between pH-sensitive liposomes and model membranes. Biophys Chem (2003) 0.91
In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm (2006) 0.91
Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine (2003) 0.91
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res (2008) 0.90
Optimized in vitro and in vivo expression of proteorhodopsin: a seven-transmembrane proton pump. Protein Expr Purif (2007) 0.90
Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res (2006) 0.90
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. BMC Cancer (2011) 0.90
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther (2002) 0.90
Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. J Control Release (2005) 0.90
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res (2004) 0.89
Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. Int Immunol (2013) 0.89
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS One (2013) 0.88
Morphology of magnetically aligning DMPC/DHPC aggregates-perforated sheets, not disks. Langmuir (2006) 0.88
Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J Control Release (2010) 0.87
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res (2004) 0.87
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat (2007) 0.87
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release (2010) 0.87
An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release (2004) 0.87
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol (2009) 0.87
Disc formation in cholesterol-free liposomes during phase transition. Biochim Biophys Acta (2003) 0.87
Using NMR metabolomics to identify responses of an environmental estrogen in blood plasma of fish. Aquat Toxicol (2006) 0.87
Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev (2007) 0.87
Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res (2008) 0.86
Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm (2007) 0.85
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. PLoS One (2013) 0.85
Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity. Nanomedicine (Lond) (2011) 0.85
Large-scale preparation of thrombin from human plasma. Thromb Res (2008) 0.85
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta (2002) 0.85